Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | $1.14M | $1.03M | $81.0K | — | $90.0K |
| Revenue growth | — | — | — | — | — | — | -10.0% | -92.1% | — | — |
| Operating income | -$26.8M | -$26.9M | -$23.8M | -$22.1M | -$22.4M | -$25.0M | -$34.1M | -$51.9M | -$42.1M | -$36.2M |
| Operating margin | — | — | — | — | — | -2182.2% | -3311.1% | -64098.8% | — | -40274.4% |
| Net income | -$24.3M | -$26.6M | -$23.7M | -$21.9M | -$22.2M | -$24.8M | -$33.0M | -$48.8M | -$38.2M | -$33.9M |
| Net margin | — | — | — | — | — | -2165.6% | -3205.5% | -60269.1% | — | -37652.2% |
| EPS (diluted) | -$0.50 | -$0.40 | -$0.22 | -$4.40 | -$1.83 | -$1.20 | -$1.37 | -$1.83 | -$1.27 | -$1.09 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$20.8M | -$21.6M | -$20.6M | -$21.5M | -$21.6M | -$20.9M | $8.64M | -$47.3M | -$33.1M | -$24.6M |
| Capital expenditures | $60.0K | $24.7K | $96.1K | $64.0K | $253K | $133K | $366K | $153K | $11.0K | $104K |
| Free cash flow | -$20.8M | -$21.6M | -$20.7M | -$21.5M | -$21.9M | -$21.0M | $8.28M | -$47.5M | -$33.1M | -$24.7M |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $20.5M | $17.4M | $13.7M | $9.25M | $63.6M | $77.8M | $109M | $76.7M | $72.9M | $48.0M |
| Total assets | $22.5M | $18.3M | $14.9M | $11.7M | $66.4M | $80.4M | $114M | $81.4M | $76.9M | $51.8M |
| Total liabilities | $4.52M | $4.67M | $6.08M | $6.03M | $5.08M | $6.84M | $47.7M | $45.1M | $44.1M | $43.9M |
| Shareholders' equity | $18.0M | $13.7M | $8.81M | $5.64M | $61.3M | $73.5M | $66.5M | $36.4M | $32.8M | $7.83M |
| Retained earnings | -$137M | -$163M | -$187M | -$209M | -$231M | -$256M | -$289M | -$338M | -$376M | -$410M |
| Shares (wtd avg diluted) | 55.8M | 80.1M | 116M | 5.49M | 17.5M | 20.6M | 24.1M | 26.6M | 30.1M | 31.2M |
Every figure is extracted from Actinium Pharmaceuticals, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.